TuisPSTV • NASDAQ
add
Plus Therapeutics Inc
Vorige sluiting
$0,47
Dagwisseling
$0,44 - $0,47
Jaarwisseling
$0,16 - $2,31
Markkapitalisasie
44,39 m USD
Gemiddelde volume
11,58 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,39 m | 8,68% |
Bedryfskoste | 1,68 m | -23,65% |
Netto inkomste | 5,15 m | 275,20% |
Netto winsgrens | 370,58 | 261,21% |
Wins per aandeel | -0,01 | 98,56% |
EBITDA | -1,46 m | 58,58% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 6,88 m | -18,45% |
Totale bates | 10,35 m | -7,69% |
Totale aanspreeklikheid | 7,32 m | -61,16% |
Totale ekwiteit | 3,03 m | — |
Uitstaande aandele | 99,26 m | — |
Prys om te bespreek | 15,66 | — |
Opbrengs op bates | -34,32% | — |
Opbrengs op kapitaal | 37,44% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 5,15 m | 275,20% |
Kontant van bedrywe | -5,80 m | -404,17% |
Kontant van beleggings | -4,63 m | -21,83% |
Kontant van finansiering | 2,80 m | -59,84% |
Netto kontantverandering | -7,63 m | -479,61% |
Beskikbare kontantvloei | -5,31 m | -186,64% |
Meer oor
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Gestig
1996
Hoofkwartier
Webwerf
Werknemers
21
